Fondaparinux Population Pharmacokinetic to Morbid Obese Patients in Post-operatory Bariatric Surgery

Fondaparinux Population Pharmacokinetic to Morbid Obese Patients in Post-operatory Bariatric Surgery

After bariatric surgery , thromboembolics complications are major cause of mortality. However, in obese patients, thromboprophylaxia is a controversy. Fondaparinux' efficacy is superior to HBPM, and is a good treatment for this population. Pharmacokinetics information with Fondaparinux in this population are rare.

We proposed a bicentric study cohort of obese patients (BMI > 40 kg/m2) treated by 1 day injection of Fondaparinux 2.5 mg after bypass surgery. Anti-Xa activity of Fondaparinux will be measured 4 times during hospitalisation for each patient to realise a pharmacokinetic modelisation of Fondaparinux. Haemorrhage and thromboembolics events will be collected.

Inclusion Criteria:

• Age ≥ 18 years old
• requiring a bariatric surgery
• requiring an antithrombotics prophylaxis
• having a morbid obesity based on a BMI >40 kg/m2
• having signed the inform consent form

Exclusion Criteria:

• contra-indication to fondaparinux
• history of heparin induced thrombopenia (HIT)
• platelets < 100 G/l
• requiring an effective antithrombotic treatment